Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2010

View Archived Issues

Merck & Co. claims new HIV integrase inhibitors

Novartis discovers new orexin receptor antagonists

Zydus-Cadila identifies new GPR119 receptor agonists

Miraculins launches ELISA kit to detect PSP94 in urine

CCR5 gene disruption by SB-728 in HSPCs may be new approach to treat HIV/AIDS

Health Canada conditionally approves Tasigna for CML

ISV-303 enters phase I/II trial for postsurgical ocular pain

Takepron approved for additional indication in Japan

Nesina in combination with thiazolidinediones approved in Japan for diabetes

Soligenix receives FDA grant to advance orBec in gastrointestinal GVHD

FCGR2B gene variant is associated with protection from malaria

Daiichi Sankyo claims new ligands of voltage-gated calcium channel subunit alpha2/delta

Baxter acquires exclusive commercial rights to Glassia in U.S. and other countries

Banyu Pharma and Merck & Co. present new PKB inhibitors

Amgen reports pipeline update for second quarter 2010

WHO grants prequalification status to Pfizer's Prevenar 13

Gruenenthal discloses new bradykinin B1 receptor antagonists

Bristol-Myers Squibb offers pipeline update for Q2 2010

Hepatitis E vaccine HEV-239 is safe in phase III trial in healthy adults

AstraZeneca presents new inhibitors of GlyT-1

Perampanel shows promise in phase III trial in epilepsy

Medivir partners with Daewoong to distribute Xerclear in South Korea

Sunitinib/erlotinib improves progression-free survival in NSCLC

Synthetic calcium phosphate ceramics induce osteogenesis in preclinical study

FDA grants orphan drug status for brain cancer product 2B3-101

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...